Molecular mechanisms of preeclampsia

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 10, 2015, Pages

  Hod, Tammy ^a   Cerdeira, Ana Sofia ^a,b   Ananth Karumanchi, S ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Howard Hughes Medical Institute ^*  (Portugal)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ARTICLE; FETUS MORTALITY; GESTATION PERIOD; HUMAN; MATERNAL HYPERTENSION; MATERNAL MORBIDITY; MATERNAL MORTALITY; NONHUMAN; PATHOGENESIS; PLACENTA DISORDER; PREECLAMPSIA; PROTEINURIA; FEMALE; METABOLISM; PHYSIOLOGY; PLACENTA; PLACENTA DISEASES; PRE-ECLAMPSIA; PREGNANCY; PRENATAL DIAGNOSIS; PROCEDURES; SIGNAL TRANSDUCTION;

ANGIOGENESIS INDUCING AGENTS; BIOMARKERS; FEMALE; HUMANS; PLACENTA; PLACENTA DISEASES; PRE-ECLAMPSIA; PREGNANCY; PRENATAL DIAGNOSIS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84943329312     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a023473     Document Type: Article

References (170)

1. Ahmed A. 2011. New insights into the etiology of preeclampsia: Identification of key elusive factors for the vascular complications. Thromb Res 127: S72-S75.
2. Ahmad S, Ahmed A. 2004. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 95: 884-891.
3. Ahmed A, Cudmore MJ. 2009. Can the biology of VEGF and haem oxygenases help solve pre-eclampsia? Biochem Soc Trans 37: 1237-1242.
4. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. 2011. Prediction of early, intermediate and late preeclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 31: 66-74.
5. Akolekar R, Syngelaki A, Poon L,Wright D, Nicolaides KH. 2013. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 33: 8-15.
6. Ambati BK,Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, Albuquerque RJ, Richter E, Sakurai E, Newcomb MT, et al. 2006. Corneal avascularity is due to soluble VEGF receptor-1. Nature 443: 993-997.
7. American College of Obstetricians and Gynecologists; Task Force onHypertension in Pregnancy. 2013. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 122: 1122-1131.
8. Anton L,Merrill DC,Neves LA, Stovall K, Gallagher PE, Diz DI,Moorefield C, Gruver C, Ferrario CM, Brosnihan KB. 2008. Activation of local chorionic villi angiotensin II levels but not angiotensin (1-7) in preeclampsia. Hypertension 51: 1066-1072.
9. Basso O, Rasmussen S,Weinberg CR,Wilcox AJ, Irgens LM, Skjaerven R. 2006. Trends in fetal and infant survival following preeclampsia. JAMA 296: 1357-1362.
10. Bellamy L, Casas JP, Hingorani AD,Williams DJ. 2007. Preeclampsia and risk of cardiovascular disease and cancer in later life: Systematic review and meta-analysis. BMJ 335: 974.
11. Bello N, Rendon IS, Arany Z. 2013. The relationship between pre-eclampsia and peripartum cardiomyopathy: A systematic review and meta-analysis. J Am Coll Cardiol 62: 1715-1723.
12. Benton SJ, Hu Y, Xie F, Kupfer K, Lee SW, Magee LA, von Dadelszen P. 2011. Angiogenic factors as diagnostic tests for preeclampsia: A performance comparison between two commercial immunoassays. Am J Obstet Gynecol 205: 469 e461-e468.
13. Bergmann A, Ahmad S, Cudmore M, GruberAD,Wittschen P, Lindenmaier W, Christofori G, Gross V, Gonzalves A, Grone HJ, et al. 2010. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med 14: 1857-1867.
14. Brosens I, Robertson WB, Dixon HG. 1967. The physiological response of the vessels of the placental bed to normal pregnancy. J Pathol Bacteriol 93: 569-579.
15. Buhimschi IA, Nayeri UA, Zhao G, Shook LL, Pensalfini A, Funai EF, Bernstein IM, Glabe CG, Buhimschi CS. 2014. Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia. Sci Transl Med 6: 245ra292.
16. Burton GJ, YungHW. 2011. Endoplasmic reticulum stress in the pathogenesis of early-onset pre-eclampsia. Pregnancy Hypertens 1: 72-78.
17. Burwick RM, Feinberg BB. 2013. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 34: 201-203.
18. Burwick RM, Fichorova RN, Dawood HY, Yamamoto HS, Feinberg BB. 2013. Urinary excretion of C5b-9 in severe preeclampsia: Tipping the balance of complement activation in pregnancy. Hypertension 62: 1040-1045.
19. Buurma AJ, Penning ME, Prins F, Schutte JM, Bruijn JA, Wilhelmus S, Rajakumar A, Bloemenkamp KW, Karumanchi SA, Baelde HJ. 2013. Preeclampsia is associated with the presence of transcriptionally active placental fragments in the maternal lung. Hypertension 62: 608-613.
20. Caniggia I, Mostachfi H, Winter J, Gassmann M, Lye SJ, Kuliszewski M, Post M. 2000. Hypoxia-inducible factor- 1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFβ3. J Clin Invest 105: 577-587.
21. Cerdeira AS, Rajakumar A, Royle CM, Lo A, Husain Z, Thadhani RI, Sukhatme VP, Karumanchi SA, Kopcow HD. 2013. Conversion of peripheral blood NK cells to a decidual NK-like phenotype by a cocktail of defined factors. J Immunol 190: 3939-3948.
22. Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee Kim Y, Goncalves LF, Gomez R, Edwin S. 2004. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Am J Obstet Gynecol 190: 1541-1547; discussion 1547-1550.
23. Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, Bujold E, Goncalves L, Gomez R, Edwin S, et al. 2005. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 17: 3-18.
24. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, Dong Z, Tarca A, Gaurav B, Hassan SS. 2011. Maternal plasma concentrations of angiogenic/ anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage areawith the suspicion of preeclampsia. J Matern Fetal Neona 24: 1187-1207.
25. Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. 2014. Pre-eclampsia part 1: Current understanding of its pathophysiology. Nat Rev Nephrol 10: 466-480.
26. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. 2001. Association of maternal endothelial dysfunction with preeclampsia. JAMA 285: 1607-1612.
27. Chappell JC, Taylor SM, Ferrara N, Bautch VL. 2009. Local guidance of emerging vessel sprouts requires soluble Flt- 1. Dev Cell 17: 377-386.
28. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, Simpson N, Waugh J, Anumba D, Kenny LC, et al. 2013. Diagnostic accuracy of placental growth factor inwomenwith suspected preeclampsia: Aprospective multicenter study. Circulation 128: 2121-2131.
29. Chen CW, Jaffe IZ, Karumanchi SA. 2014. Pre-eclampsia and cardiovascular disease. Cardiovasc Res 101: 579-586.
30. Conrad KP, Shroff SG. 2011. Effects of relaxin on arterial dilation, remodeling, and mechanical properties. Curr Hypertens Rep 13: 409-420.
31. Croy BA, Ashkar AA, Minhas K, Greenwood JD. 2000. Can murine uterine natural killer cells give insights into the pathogenesis of preeclampsia? J Soc Gynecol Investig 7: 12-20.
32. Cudmore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, Chudasama K, Devey LR, Wigmore SJ, Abbas A, Hewett PW, et al. 2007. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 115: 1789-1797.
33. Cui Y, Wang W, Dong N, Lou J, Srinivasan DK, Cheng W, Huang X, Liu M, Fang C, Peng J, et al. 2012. Role of corin in trophoblast invasion and uterine spiral artery remodelling in pregnancy. Nature 484: 246-250.
34. Damsky CH, Fisher SJ. 1998. Trophoblast pseudo-vasculogenesis: Faking it with endothelial adhesion receptors. Curr Opin Cell Biol 10: 660-666.
35. Duley L. 2009. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 33: 130-137.
36. Eremina V, Quaggin SE. 2004. The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 13: 9-15.
37. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE. 2003. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707-716.
38. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, et al. 2008. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358: 1129-1136.
39. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM. 2009. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 54: 652-658.
40. Fan X, Rai A, Kambham N, Sung JF, Singh N, Petitt M, Dhal S, Agrawal R, Sutton RE, Druzin ML, et al. 2014. Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications. J Clin Invest 124: 4941-4952.
41. Fisher SJ. 2004. The placental problem: Linking abnormal cytotrophoblast differentiation to the maternal symptoms of preeclampsia. Reprod Biol Endocrinol 2: 53.
42. Garovic VD, Wagner SJ, Petrovic LM, Gray CE, Hall P, Sugimoto H, Kalluri R, Grande JP. 2007. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant 22: 1136-1143.
43. Gilbert JS, Babcock SA, Granger JP. 2007. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase- 1 expression. Hypertension 50: 1142-1147.
44. Gilbert JS, Gilbert SA, Arany M, Granger JP. 2009. Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension 53: 399-403.
45. Gilbert JS, Verzwyvelt J, Colson D, Arany M, Karumanchi SA, Granger JP. 2010. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemiainduced hypertension. Hypertension 55: 380-385.
46. Ginath S, Lurie S, Golan A, Amsterdam A, Sandbank J, Sadan O, Kovo M. 2014. The expression of heparanase in normal and preeclamptic placentas. J Matern Fetal NeonatalMed: 1-5. doi: 10.3109/14767058.2014.962506.
47. Goswami D, Tannetta DS, Magee LA, Fuchisawa A, Redman CW, Sargent IL, von Dadelszen P. 2006. Excess syncytiotrophoblast microparticle shedding is a feature of earlyonset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta 27: 56-61.
48. Gu Y, Lewis DF, Wang Y. 2008. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 93: 260-266.
49. Hagmann H, Thadhani R, Benzing T, Karumanchi SA, Stepan H. 2012. The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin Chem 58: 837-845.
50. He H, Venema VJ, Gu X, Venema RC,MarreroMB, Caldwell RB. 1999. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 274: 25130-25135.
51. Herse F, Dechend R, Harsem NK,Wallukat G, Janke J, Qadri F, Hering L, Muller DN, Luft FC, Staff AC. 2007. Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia. Hypertension 49: 604- 611.
52. Hiby SE, Walker JJ, O'Shaughnessy KM, Redman CW, Carrington M, Trowsdale J, Moffett A. 2004. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J ExpMed 200: 957-965.
53. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. 1998. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci 95: 9349-9354.
54. Hladunewich MA, Steinberg G, Karumanchi SA, Levine RJ, Keating S, Kingdom J, Keunen J. 2009. Angiogenic factor abnormalities and fetal demise in a twin pregnancy. Nat Rev Nephrol 5: 658-662.
55. Hubel CA, Snaedal S, Ness RB, Weissfeld LA, Geirsson RT, Roberts JM, Arngrimsson R. 2000. Dyslipoproteinaemia in postmenopausal women with a history of eclampsia. BJOG 107: 776-784.
56. Huckle WR, Roche RI. 2004. Post-transcriptional control of expression of sFlt-1, an endogenous inhibitor of vascular endothelial growth factor. J Cell Biochem 93: 120-132.
57. Huppertz B, Herrler A. 2005. Regulation of proliferation and apoptosis during development of the preimplantation embryo and the placenta. Birth Defects Res C Embryo Today 75: 249-261.
58. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
59. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, et al. 2004. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165: 35-52.
60. Irani RA, Zhang Y, Zhou CC, Blackwell SC, Hicks MJ, Ramin SM, Kellems RE, Xia Y. 2010. Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-α signaling. Hypertension 55: 1246-1253.
61. Irgens HU, Reisaeter L, Irgens LM, Lie RT. 2001. Long term mortality of mothers and fathers after pre-eclampsia: Population based cohort study. BMJ 323: 1213-1217.
62. Jayet PY, Rimoldi SF, Stuber T, Salmon CS, Hutter D, Rexhaj E, Thalmann S, Schwab M, Turini P, Sartori-Cucchia C, et al. 2010. Pulmonary and systemic vascular dysfunction in young offspring of mothers with preeclampsia. Circulation 122: 488-494.
63. Kajantie E, Eriksson JG, Osmond C, Thornburg K, Barker DJ. 2009. Pre-eclampsia is associated with increased risk of stroke in the adult offspring: The Helsinki birth cohort study. Stroke 40: 1176-1180.
64. Kalkunte SS, Neubeck S, Norris WE, Cheng SB, Kostadinov S, Vu Hoang D, Ahmed A, von Eggeling F, Shaikh Z, Padbury J, et al. 2013. Transthyretin is dysregulated in preeclampsia, and its native form prevents the onset of disease in a preclinical mouse model. Am J Pathol 183: 1425-1436.
65. Kamba T, McDonald DM. 2007. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96: 1788-1795.
66. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, et al. 2006. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290: H560-H576.
67. Kang DH, Anderson S, Kim YG, Mazzalli M, Suga S, Jefferson JA, Gordon KL, Oyama TT, Hughes J, Hugo C, et al. 2001a. Impaired angiogenesis in the aging kidney: Vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis 7: 601-611.
68. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. 2001b. Impaired angiogenesis in the remnant kidney model. II: Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 12: 1448-1457.
69. Karumanchi SA, Maynard SE, Stillman IE, Epstein FH, Sukhatme VP. 2005. Preeclampsia: A renal perspective. Kidney Int 67: 2101-2113.
70. Kendall RL, Thomas KA. 1993. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci 90: 10705- 10709.
71. Khong TY, De Wolf F, Robertson WB, Brosens I. 1986. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by smallfor- gestational age infants. Br J Obstet Gynaecol 93: 1049-1059.
72. Knudsen UB, Kronborg CS, von Dadelszen P, Kupfer K, Lee S-W, Vittinghus E, Allen JG, Redman CW. 2012. A single rapid point-of-care placental growth factor determination as an aid in the diagnosis of preeclampsia. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 2: 8-15.
73. Koopman LA, Kopcow HD, Rybalov B, Boyson JE, Orange JS, Schatz F, Masch R, Lockwood CJ, Schachter AD, Park PJ, et al. 2003. Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential. J Exp Med 198: 1201-1212.
74. Kumasawa K, Ikawa M, Kidoya H, Hasuwa H, Saito-Fujita T, Morioka Y, Takakura N, Kimura T, Okabe M. 2011. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci 108: 1451-1455.
75. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, Mazaki-Tovi S, Gotsch F, Edwin SS, Gomez R, et al. 2009. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and antiangiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neona 22: 1021-1038.
76. Lam C, Lim KH, Karumanchi SA. 2005. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 46: 1077-1085.
77. Lapaire O, HolzgreveW, Oosterwijk JC, Brinkhaus R, Bianchi DW. 2007. Georg Schmorl on trophoblasts in the maternal circulation. Placenta 28: 1-5.
78. Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH. 2002. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol 283: L555-L562.
79. Levine RJ, LindheimerMD. 2009. First-trimester prediction of early preeclampsia: A possibility at last! Hypertension 53: 747-748.
80. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, et al. 2004. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672-683.
81. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, et al. 2006a. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355: 992- 1005.
82. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, et al. 2006b. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355: 992- 1005.
83. Levine RJ, Vatten LJ, Horowitz GL, Qian C, Romundstad PR, Yu KF, Hollenberg AN, Hellevik AI, Asvold BO, Karumanchi SA. 2009. Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: Nested case-control and population based study. BMJ 339: b4336.
84. Levytska K, Kingdom J, Baczyk D, Drewlo S. 2013. Heme oxygenase-1 in placental development and pathology. Placenta 34: 291-298.
85. Li Z, Zhang Y, YingMa J, Kapoun AM, Shao Q, Kerr I, Lam A, O'Young G, Sannajust F, Stathis P, et al. 2007. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50: 686-692.
86. Llurba E, Marsal G, Sanchez O, Dominguez C, Alijotas-Reig J, Carreras E, Cabero L. 2012. Angiogenic and antiangiogenic factors before and after resolution of maternal mirror syndrome. Ultrasound Obstet Gynecol 40: 367-369.
87. Lu F, Longo M, Tamayo E, ManerW, Al-Hendy A, Anderson GD, Hankins GD, Saade GR. 2007. The effect of overexpression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 196: 396 e391-e397; discussion 396 e397.
88. Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. 2009. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension 53: 944-951.
89. Maharaj AS, Walshe TE, Saint-Geniez M, Venkatesha S, Maldonado AE, Himes NC, Matharu KS, Karumanchi SA, D'Amore PA. 2008. VEGF and TGF-β are required for the maintenance of the choroid plexus and ependyma. J Exp Med 205: 491-501.
90. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, et al. 2006. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116: 2610-2621.
91. Mannisto T, Karumanchi SA, Pouta A, Vaarasmaki M,Mendola P, Miettola S, Surcel HM, Bloigu A, Ruokonen A, Jarvelin MR, et al. 2013. Preeclampsia, gestational hypertension and subsequent hypothyroidism. Pregnancy Hypertens 3: 21-27.
92. Mano Y, Kotani T, Shibata K, Matsumura H, Tsuda H, Sumigama S, Yamamoto E, Iwase A, Senga T, Kikkawa F. 2011. The loss of endoglin promotes the invasion of extravillous trophoblasts. Endocrinology 152: 4386-4394.
93. Mattot V, Moons L, Lupu F, Chernavvsky D, Gomez RA, Collen D, Carmeliet P. 2002. Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. J Am Soc Nephrol 13: 1548-1560.
94. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, et al. 2003. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649-658.
95. Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA. 2005. Soluble fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 57: 1R-7R.
96. McDonald SD, Han Z,WalshMW, Gerstein HC, Devereaux PJ. 2010. Kidney disease after preeclampsia: A systematic review and meta-analysis. Am J Kidney Dis 55: 1026-1039.
97. McGuane JT, Danielson LA, Debrah JE, Rubin JP, Novak J, Conrad KP. 2011. Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans. Hypertension 57: 1151-1160.
98. Moore AG, Young H, Keller JM, Ojo LR, Yan J, Simas TA, Maynard SE. 2012. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neona 25: 2651-2657.
99. Nishimoto F, Sakata M, Minekawa R, Okamoto Y, Miyake A, Isobe A, Yamamoto T, Takeda T, Ishida E, Sawada K, et al. 2009.Metal transcription factor-1 is involved in hypoxiadependent regulation of placenta growth factor in trophoblast- derived cells. Endocrinology 150: 1801-1808.
100. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. 2010. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 122: 478-487.
101. Ohkuchi A, Hirashima C, Suzuki H, Takahashi K, Yoshida M, Matsubara S, Suzuki M. 2010. Evaluation of a newand automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res 33: 422-427.
102. Park M, Lee ST. 1999. The fourth immunoglobulin-like loop in the extracellular domain of FLT-1, a VEGF receptor, includes a major heparin-binding site. Biochem Biophys Res Commun 264: 730-734.
103. Parrish MR, Murphy SR, Rutland S, Wallace K, Wenzel K, Wallukat G, Keiser S, Ray LF, Dechend R, Martin JN, et al. 2010. The effect of immune factors, tumor necrosis factor- α, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am J Hypertens 23: 911-916.
104. Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD. 2008. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 100: 282- 284.
105. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, Hacker MR, Rhee JS, Mitchell J,Mahmood F, et al. 2012. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485: 333-338.
106. Perni U, Sison C, Sharma V, Helseth G, Hawfield A, Suthanthiran M, August P. 2012. Angiogenic factors in superimposed preeclampsia: A longitudinal study of women with chronic hypertension during pregnancy. Hypertension 59: 740-746.
107. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. 1995. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci 92: 905-909.
108. Polliotti BM, Fry AG, Saller DN,Mooney RA, Cox C, Miller RK. 2003. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 101: 1266-1274.
109. Poon LC, Kametas NA,Maiz N, Akolekar R, Nicolaides KH. 2009. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 53: 812-818.
110. Powe CE, Levine RJ, Karumanchi SA. 2011. Preeclampsia, a disease of the maternal endothelium: The role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 123: 2856-2869.
111. Rahimi N, Golde TE, Meyer RD. 2009. Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells. Cancer Res 69: 2607-2614.
112. Rajakumar A, Michael HM, Rajakumar PA, Shibata E, Hubel CA, Karumanchi SA, Thadhani R,Wolf M, Harger G, Markovic N. 2005. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 26: 563-573.
113. Rajakumar A, Cerdeira AS, Rana S, Zsengeller Z, Edmunds L, Jeyabalan A, Hubel CA, Stillman IE, Parikh SM, Karumanchi SA. 2012. Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension 59: 256-264.
114. RammaW, Ahmed A. 2014. Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia. J Reprod Immunol 101-102: 153-160.
115. Rana S, Cerdeira AS, Wenger J, Salahuddin S, Lim KH, Ralston SJ, Thadhani RI, Karumanchi SA. 2012. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS ONE 7: e48259.
116. Rana S, Schnettler WT, Powe C, Wenger J, Salahuddin S, Cerdeira AS, Verlohren S, Perschel FH, Arany Z, Lim KH, et al. 2013. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy 32: 189-201.
117. Rana S, Rajakumar A, Geahchan C, Salahuddin S, Cerdeira AS, Burke SD, George EM, Granger JP, Karumanchi SA. 2014. Ouabain inhibits placental sFlt1 production by repressing HSP27-dependent HIF-1α pathway. FASEB J 28: 4324-4334.
118. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. 2005. Cardiovascular health after maternal placental syndromes (CHAMPS): Population-based retrospective cohort study. Lancet 366: 1797-1803.
119. Redman CW. 2008. The endoplasmic reticulum stress of placental impoverishment. Am J Pathol 173: 311-314.
120. Redman CW, Sargent IL. 2000. Placental debris, oxidative stress and pre-eclampsia. Placenta 21: 597-602.
121. Redman CW, Tannetta DS, Dragovic RA, Gardiner C, Southcombe JH, Collett GP, Sargent IL. 2012. Review: Does size matter? Placental debris and the pathophysiology of pre-eclampsia. Placenta 33: S48-S54.
122. Robbins SG, Conaway JR, Ford BL, Roberto KA, Penn JS. 1997. Detection of vascular endothelial growth factor (VEGF) protein in vascular and non-vascular cells of the normal and oxygen-injured rat retina. Growth Factors 14: 229-241.
123. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. 1989. Preeclampsia: An endothelial cell disorder. Am J Obstet Gynecol 161: 1200-1204.
124. Robillard PY, Dekker G, Chaouat G, Hulsey TC, Saftlas A. 2011. Epidemiological studies on primipaternity and immunology in preeclampsia-A statement after twelve years of workshops. J Reprod Immunol 89: 104-117.
125. Robson A, Harris LK, Innes BA, Lash GE, Aljunaidy MM, Aplin JD, Baker PN, Robson SC, Bulmer JN. 2012. Uterine natural killer cells initiate spiral artery remodeling in human pregnancy. FASEB J 26: 4876-4885.
126. Rolfo A, Attini R, Nuzzo AM, Piazzese A, Parisi S, Ferraresi M, Todros T, Piccoli GB. 2012. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int 83: 177-181.
127. Romero R, Chaiworapongsa T. 2013. Preeclampsia: A link between trophoblast dysregulation and an antiangiogenic state. J Clin Invest 123: 2775-2777.
128. Saad AF, Kechichian T, Yin H, Sbrana E, Longo M, Wen M, Tamayo E, Hankins GD, Saade GR, Costantine MM. 2014. Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia. Reprod Sci 21: 138-145.
129. Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi SA, Lim KH. 2007. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. AmJ Obstet Gynecol 197: 28 e21-e26.
130. Sattar N, Ramsay J, Crawford L, Cheyne H, Greer IA. 2003. Classic and novel risk factor parameters in women with a history of preeclampsia. Hypertension 42: 39-42.
131. Saxena AR,Karumanchi SA, Brown NJ, Royle CM,McElrath TF, SeelyEW. 2010. Increased sensitivity to angiotensin II is present postpartum in women with a history of hypertensive pregnancy. Hypertension 55: 1239-1245.
132. Schiettecatte J, Russcher H, Anckaert E, Mees M, Leeser B, Tirelli AS, Fiedler GM, Luthe H, Denk B, Smitz J. 2010. Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin Biochem 43: 768-770.
133. Seidman DS, Laor A, Gale R, Stevenson DK, Mashiach S, Danon YL. 1991. Pre-eclampsia and offspring's blood pressure, cognitive ability and physical development at 17-years-of-age. Br J Obstet Gynaecol 98: 1009-1014.
134. Sela S, Itin A, Natanson-Yaron S, Greenfield C, Goldman-Wohl D, Yagel S, Keshet E. 2008. A novel human-specific soluble vascular endothelial growth factor receptor 1: Cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 102: 1566-1574.
135. Sela S, Natanson-Yaron S, Zcharia E, Vlodavsky I, Yagel S, Keshet E. 2011. Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase. Circ Res 108: 1063- 1070.
136. Siddiqui AH, Irani RA, Blackwell SC, Ramin SM, Kellems RE, Xia Y. 2010. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: Correlation with disease severity. Hypertension 55: 386-393.
137. Sitohy B, Nagy JA, Jaminet SC, Dvorak HF. 2011. Tumorsurrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy. Cancer Res 71: 7021- 7028.
138. Smith GC, Pell JP,Walsh D. 2001. Pregnancy complications and maternal risk of ischaemic heart disease: A retrospective cohort study of 129,290 births. Lancet 357: 2002- 2006.
139. Stepan H, Faber R. 2006. Elevated sFlt1 level and preeclampsia with parvovirus-induced hydrops. N Engl J Med 354: 1857-1858.
140. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R. 2003. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278: 12605- 12608.
141. Sunderji S, Gaziano E, Wothe D, Rogers LC, Sibai B, Karumanchi SA, Hodges-Savola C. 2010. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: A prospective clinical study. Am J Obstet Gynecol 202: 40 e41-e47.
142. Tang JR, Markham NE, Lin YJ, McMurtry IF, Maxey A, Kinsella JP, Abman SH. 2004. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol 287: L344-L351.
143. Tang JR, Karumanchi SA, Seedorf G, Markham N, Abman SH. 2012. Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: Linking preeclampsia with bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 302: L36-L46.
144. Tannetta DS, Dragovic RA, Gardiner C, Redman CW, Sargent IL. 2013. Characterisation of syncytiotrophoblast vesicles in normal pregnancy and pre-eclampsia: Expression of Flt-1 and endoglin. PLoS ONE 8: e56754.
145. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, SchaarschmidtW, Jank A, Kribs A, Cornely OA, Kreyssig C, et al. 2011. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 124: 940-950.
146. Thomas CP, Andrews JI, Liu KZ. 2007. Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta. FASEB J 21: 3885-3895.
147. Tissot van Patot MC, Bendrick-Peart J, Beckey VE, Serkova N, Zwerdlinger L. 2004. Greater vascularity, lowered HIF- 1/DNA binding, and elevated GSH as markers of adaptation to in vivo chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 287: L525-L532.
148. Unemori E, Sibai B, Teichman SL. 2009. Scientific rationale and design of a phase I safety study of relaxin in women with severe preeclampsia. Ann NY Acad Sci 1160: 381- 384.
149. Vatten LJ, Romundstad PR, Holmen TL, Hsieh CC, Trichopoulos D, Stuver SO. 2003. Intrauterine exposure to preeclampsia and adolescent blood pressure, body size, and age at menarche in female offspring. Obstet Gynecol 101: 529-533.
150. Veas CJ, Aguilera VC, Munoz IJ, Gallardo VI, Miguel PL, Gonzalez MA, Lamperti LI, Escudero CA, Aguayo CR. 2011. Fetal endothelium dysfunction is associated with circulating maternal levels of sE-selectin, sVCAM1, and sFlt-1 during pre-eclampsia. J Matern FetalNeonatal Med 24: 1371-1377.
151. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, et al. 2006. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12: 642-649.
152. Verdonk K, VisserW, Russcher H, Danser AH, Steegers EA, van den Meiracker AH. 2012. Differential diagnosis of preeclampsia: Remember the soluble fms-like tyrosine kinase 1/placental growth factor ratio. Hypertension 60: 884-890.
153. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H. 2010. An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia.AmJ Obstet Gynecol 202: 161 e161-161 e111.
154. Verlohren S, Herraiz I, Lapaire O, Schlembach D,Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, et al. 2012. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 206: 58 e51-e58.
155. Veron D, Villegas G, Aggarwal PK, Bertuccio C, Jimenez J, Velazquez H, Reidy K, Abrahamson DR, Moeckel G, Kashgarian M, et al. 2012. Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts αVβ3 integrin signaling in the glomerulus. PLoS ONE 7: e40589.
156. Vigneau C, Lorcy N, Dolley-Hitze T, Jouan F, Arlot-Bonnemains Y, Laguerre B, Verhoest G, Goujon JM, Belaud-Rotureau MA, Rioux-Leclercq N. 2014. All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia- like syndrome': A RARe study. Nephrol Dial Transplant 29: 325-332.
157. Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. 2008. Preeclampsia and the risk of end-stage renal disease. N Engl J Med 359: 800-809.
158. Vuorela P, Helske S, Hornig C, Alitalo K,Weich H, Halmesmaki E. 2000. Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet Gynecol 95: 353-357.
159. Wang CN, Chang SD, Peng HH, Lee YS, Chang YL, Cheng PJ, Chao AS, Wang TH, Wang HS. 2010. Change in amniotic fluid levels of multiple anti-angiogenic proteins before development of preeclampsia and intrauterine growth restriction. J Clin Endocrinol Metab 95: 1431-1441.
160. Wang IK,Muo CH, Chang YC, Liang CC, Chang CT, Lin SY, Yen TH, Chuang FR, Chen PC, Huang CC, et al. 2013a. Association between hypertensive disorders during pregnancy and end-stage renal disease: A population-based study. CMAJ 185: 207-213.
161. Wang IK, Muo CH, Chang YC, Liang JC, Chang CT, Lin SY, Yen TH, Chuang FR, Chen PC, Huang CC, et al. 2013b. Association between hypertensive disorders during pregnancy and end-stage renal disease: A population-based study. CMAJ 185: 207-213.
162. Wilson BJ,Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, Smith WC. 2003. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: Results from cohort study. BMJ 326: 845.
163. Wolf M, Hubel CA, Lam C, Sampson M, Ecker JL, Ness RB, Rajakumar A, Daftary A, Shakir AS, Seely EW, et al. 2004. Preeclampsia and future cardiovascular disease: Potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab 89: 6239-6243.
164. Xinaris C, Benedetti V, Rizzo P, Abbate M, Corna D, Azzollini N, Conti S, Unbekandt M, Davies JA,Morigi M, et al. 2012. In vivo maturation of functional renal organoids formed from embryonic cell suspensions. J AmSoc Nephrol 23: 1857-1868.
165. Yu XD, Branch DW, Karumanchi SA, Zhang J. 2012. Preeclampsia and retinopathy of prematurity in preterm births. Pediatrics 130: e101-e107.
166. Yuan HT, Haig D, Ananth Karumanchi S. 2005. Angiogenic factors in the pathogenesis of preeclampsia. Curr Top Dev Biol 71: 297-312.
167. Zhao S, Gu Y, Fan R, Groome LJ, Cooper D, Wang Y. 2010. Proteases and sFlt-1 release in the human placenta. Placenta 31: 512-518.
168. Zhou Y,McMaster M,Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ. 2002. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 160: 1405-1423.
169. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, Xia Y. 2008. Angiotensin receptor agonistic autoantibodies induce preeclampsia in pregnant mice. Nat Med 14: 855-862.
170. Zhou Y, Gormley MJ, Hunkapiller NM, Kapidzic M, Stolyarov Y, FengV, Nishida M, Drake PM, Bianco K,Wang F, et al. 2013. Reversal of gene dysregulation in cultured cytotrophoblasts reveals possible causes of preeclampsia. J Clin Invest 123: 2862-2872.